QSAR Models Based on Lipophilicity for Quinoxaline 1,4-di-n-Oxides as Antitubercular Candidates

P. R. DUCHOWICZ; E. VICENTE; A. G. MERCADER; S. PÉREZ-SILANES; I. ALDANA; F. M. FERNÁNDEZ; E. A. CASTRO; A. MONGE

Vienna

Simposio; XXth International Symposium on Medicinal Chemistry; 2008

Tuberculosis (TB), an infection of Mycobacterium tuberculosis, still remains the leading cause of worldwide death among infectious diseases. The statistics indicate that 1.6 million people throughout the world die from Tuberculosis, and there were an estimated 8.8 million new cases in 2005. The current frontline therapy for tuberculosis consists of administering three or more different drugs during an extended period of time. Consequently, problems due to multidrug-resistant TB arise and it is necessary to develop new therapeutic agents in order to treat drug resistant forms of the disease. As a result of the anti-tuberculosis research project, our group published several studies in which the synthesis and biological evaluation of a large amount of quinoxalines have been described, thus leading to several compounds that showed important antitubercular activity in vitro.